MSInsight, a Paris, France-based startup specializing in precision medicine in oncology, raised €1.6M in Seed funding.
Backers included Calyseed, with participation from Plateau de Saclay Business Angels, Yes Invest, Capital Cell, and banking partners such as bpifrance.
The company intends to use the funds to finalize its technological development, demonstrate its performance in various types of cancer, and initiate the regulatory clinical validation necessary for its CE-IVD marking as an in vitro diagnostic medical device.
Led by Arnaud Cutivet, PhD, president and co-founder, MSInsight offers diagnostic solutions to identify crucial information in patients’ DNA to predict the success of treatments. In particular, the company is improving the diagnosis of Microsatellite Instability (MSI), a DNA alteration that will give them access to immunotherapy if found in a patient. It has developed MSIcare, a medical device software integrating bioinformatics algorithms and artificial intelligence models derived from its expertise to interpret the patient’s genomic data and identify information of interest. The solution proposed by MSInsight makes it possible to significantly improve the detection of the MSI biomarker in different contexts and to democratize its access thanks to an optimized interpretation interface of the results. It has already been clinically validated that this diagnosis can be made from a tumor tissue sample in different cancers.
The company is actively working to expand its application to simple blood diagnostics, paving the way for a less invasive and more accessible approach.
FinSMEs
18/03/2025